Infographic | January 14, 2022

Small Molecule Drug Substance Pandemic Complications

Source: ISR Reports

Over the past two years, ISR has asked respondents to its annual small molecule drug substance benchmarking surveys whether they encountered pandemic related complications with their outsourced manufacturing. The data show it was slightly more common for small molecule API outsourcers to experience COVID-19 related manufacturing complications in 2021 than during 2020. To learn more about small molecule API manufacturers’ performance during the pandemic, follow the link to the Small Molecule API CMO Benchmarking report preview.

access the Infographic!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Pharmaceutical Online

Please tell us more about you so that we can customize our newsletters to your specific interests:

ISR Reports